Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for infectious disease, cardiology, thyroid, general and women's health, eye health, gastrointestinal disease, and toxicology applications globally. The company is headquartered in San Diego, California.
| Revenue (TTM) | $2.67B |
| Gross Profit (TTM) | $1.20B |
| EBITDA | $484.60M |
| Operating Margin | -2.09% |
| Return on Equity | -45.90% |
| Return on Assets | 0.38% |
| Revenue/Share (TTM) | $39.27 |
| Book Value | $25.99 |
| Price-to-Book | 0.42 |
| Price-to-Sales (TTM) | 0.28 |
| EV/Revenue | 1.369 |
| EV/EBITDA | 22.78 |
| Quarterly Earnings Growth (YoY) | -77.10% |
| Quarterly Revenue Growth (YoY) | 2.80% |
| Shares Outstanding | $68.58M |
| Float | $61.17M |
| % Insiders | 0.90% |
| % Institutions | 124.20% |
Volatility is currently expanding
SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room.
SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.
QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.
QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
QuidelOrtho NASDAQ: QDEL reported second-quarter revenue growth despite continued pressure from China and a softer respiratory testing environment, while lowering its full-year outlook and withdrawing free cash flow guidance.
― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ― ― Excluding China, total revenue grew 6% both as reported and in constant currency ― ― Company updates full-year 2026 financial guidance ― SAN DIEGO, Aug. 6, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the second quarter ended June 28, 2026. Key Second Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $631 million, an increase of 3% as reported and 2% in constant currency.
Investors need to pay close attention to QDEL stock based on the movements in the options market lately.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on QDEL and any ticker you trade — then tracks every position and per-strategy win rate.
